Drivers of the Russian pharmaceutical market were discussed in Kazan
A plenary session dedicated to the Drivers of pharmaceutical market growth. Global View came first on the business agenda of the III All-Russia GMP conference with international participation Russia and the World. Management of the pharmaceutical market growth potential. The conference opened today in Kazan (Republic of Tatarstan) and will last through August 29.
The moderator of the discussion, Vladimir Shipkov, Executive Director of the Association of International Pharmaceutical Manufacturers (AIPM), referred to measures offered by the Chinese government in support of their pharmaceutical industry. One of which is shorter wait time for new drugs registration, that in turn enabled manufacturers to release and expeditiously register a new molecule of forty-five developed.
Valentina Kosenko, Deputy Head of the Federal Service for Surveillance in Healthcare talked about legislative measures in Russia used for active development of pharmaceuticals. For example, the risk-based approach in drug circulation lifts the burden off bonafide participants on the pharmaceutical market and helps identify those who are reluctant to follow government regulations.
Aleksey Alekhin, Head of the Department of Pharmaceutical and Medical Industry Development of the Russian Ministry of Industry and Trade took part in the session. He identified a number of drivers that have impact on the pharmaceutical market, i.e. interaction between key players of the pharmaceutical market, protection of intellectual property, and growing exports. Regulatory standards remain the main driver, ‘One of the regulatory reforms to be implemented by the Russian Health Ministry is the introduction of a new registration system. This will allow carrying out extended clinical trials immediately at the time of introducing medicines to patients or its commercial sales. The Russian Ministry of Industry and Trade has actively supported pharmaceutical manufacture within the frameworks of the government program.’
Business representatives from NovaMedika, Novartis, and the General Director of GeroPharm Group, Petr Rodionov, shared their views on what exactly can make a difference for the growing pharmaceutical market. ‘If we consider reasons that make industry develop in the first place and its influencing factors, we can be certain that the regulatory environment is the foundation for the industry to develop. Without the standards, supporting measures would be less effective.’
Examples of support at the regional level were sounded in the reports of the Minister of Industry and Trade of the Republic of Tatarstan, Albert Karimov, and Deputy Head of the Moscow Department for Science, Industrial Policy, and Entrepreneurship, Kristina Volkonitskaya.
The All-Russia GMP-conference will last three days. Day Two – International Day – will bring together more than twenty foreign delegations. Day Three will be dedicated the best practices.
Partners of the III All-Russia GMP Conference:
General partner – Valenta Pharm; strategic partners: Gedeon Richter, TatKhimPharmPreparaty JSC; partners of the conference: Astellas Pharma, Takeda Pharmaceuticals, TEVA; partners of the sessions: Akrihin, Amgen, Bosnalijek”, PRO.MED.CS Prague a.s., Pharmimeks, Sanofi Russia; special partners: GEROPHARM, NatsImBio.